Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1Gastrointestinal 1CNS 1

Conditions

Neuroendocrine Tumors 7Neoplasms 7Thyroid Neoplasms 6Thyroid Cancer, Papillary 6Neoplasms by Site 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Thyroid Diseases 4Thoracic Neoplasms 4Sarcoma 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Lung Neoplasms 4Lung Diseases 4Endocrine System Diseases 4Endocrine Gland Neoplasms 4Colonic Neoplasms 4Carcinoma, Bronchogenic 4Bronchial Neoplasms 4Salivary Gland Neoplasms 3Pheochromocytoma 3Paraganglioma 3Colorectal Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Medullary 3Neuroectodermal Tumors 2Neoplasms, Germ Cell and Embryonal 2Neoplasms by Histologic Type 2Multiple Endocrine Neoplasia Type 1 2

Interventions

cabozantinib 1belzutifan 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Adenoma, Islet Cell × Endocrine × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡